Evaxion A/S, a clinical-stage biotechnology company specializing in AI-powered immunology, has announced new preclinical data for its acute myeloid leukemia (AML) vaccine candidate, EVX-04. The results, which demonstrate that EVX-04 triggers strong specific T-cell responses and effectively prevents tumor growth in preclinical models, were presented at the American Society of Hematology $(ASH)$ Annual Meeting and Exposition in Orlando, Florida. EVX-04 is an off-the-shelf therapeutic cancer vaccine developed using Evaxion's proprietary AI-Immunology™ platform and targets non-conventional endogenous retrovirus (ERV) tumor antigens. The company indicates that the off-the-shelf vaccine concept underlying EVX-04 has potential applications across other hard-to-treat cancers.